Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

Switching to pemafibrate could improve adverse effects due to bezafibrate, and appeared effective against liver dysfunction in cholestatic liver disease patients with incomplete response to bezafibrate.

Keyphrases

liver injury
oxidative stress
liver fibrosis
drug induced